Medical Policy

Subject: Implantable Interstitial Glucose Sensors
Document #: MED.00121 Current Effective Date:    09/27/2017
Status: Reviewed Last Review Date:    08/03/2017


This document addresses the use of implantable interstitial glucose sensors (for example, the Eversense™ Continuous Glucose Monitoring System [Senseonics, Germantown, MD]). Such devices have been proposed as an alternative method of continuous interstitial glucose monitoring.  These devices are inserted subcutaneously into the upper arm for up to 90 days and then removed or replaced.

For more information regarding interstitial glucose monitoring, please see:

Position Statement

Investigational and Not Medically Necessary:

Use of implantable interstitial glucose sensors is considered investigational and not medically necessary for all indications.


At this time, there are no U.S. Food and Drug Administration (FDA) approved subcutaneously implanted continuous interstitial glucose monitoring (CIGM) sensors.

The available published evidence addressing the use of these devices is limited.  The largest published study to date reported the results of the PRECISE trial, a prospective pivotal trial involving 71 subjects with type 1 diabetes (Kropff, 2017).  Subjects had the Eversense device implanted for 180 days and used the device continuously throughout the study period.  Additionally, subjects underwent five 24-hour and three 8-hour in-clinic device performance assessments, as well as baseline and 2-week post-explantation visits.  At the implantation visit, one device was implanted into both upper arms of the subjects.  Subjects were allowed to choose the location and sensor to be used as the primary study sensor.  A transmitter was then worn over the primary sensor and calibrated twice daily with blood glucose testing.  The secondary sensor was used during the eight performance evaluations.  Overall, 6 subjects withdrew from the trial and an additional 6 had electronic or mechanical failure of their devices.  Data for these subjects was censored.  An additional 5 subjects required replacement of faulty sensors within 3 months.  Both subjects and investigators were blinded to the CIGM values during the performance evaluations.  However, CIGM data was available to the subjects throughout other periods of the study and was used to guide self-treatment decisions after blood glucose confirmation.  The authors noted that the performance of the Eversense device in the hypoglycemic range, (≤ 75 mg/dL), was less than the overall performance (21.7% vs. 11.6% mean absolute relative difference [MARD], p<0.001).  A significant decrease in sensor accuracy was noted in the last month of sensor operation.  HbA1c was reported to have improved from a mean of 7.45% at baseline to 7.19% at study completion (p<0.001).  Clinical performance, estimated by Clark Error Grid Analysis, indicated 99.2% of samples were in the clinically acceptable error zones A (84.3%) and B (14.9%).  Alarm performance during the in-clinic studies resulted in an 81% detection rate for hypoglycemia (< 70 mg/dL) and 88% detection rate for hyperglycemia (> 180 mg/dL).  No severe procedure- or device-related adverse events were reported.  These results are promising, but additional study is needed to more fully understand the benefits and hazards of the implantable interstitial glucose sensor over conventional transcutaneous CIGM devices.

Two smaller studies have also been made available.  The larger of them published by Dehennis and others (2015) involved 24 subjects with type 1 diabetes who had the Eversense Continuous Glucose Monitoring System implanted.  The sensors were placed under the skin of the upper arm of each subject for up to 90 days.  Each subject attended a series of 8-hour clinic sessions performed every 14 days.  During these sessions, sensor glucose values were compared with venous blood glucose reference measurements collected every 15 minutes.  Most (22 of 24) sensors reported glucose values for the entire 90 days.  No serious adverse events were noted. 

The other was a small cohort study involving 12 subjects with type 1 diabetes who underwent implantation with the Eversense sensor in the upper arm and were monitored during in-home use for up to 90 days (Wang, 2015).  The purpose of the trial was to evaluate the nocturnal sensor attenuation concept.  Additionally, the sensitivity and specificity of the nocturnal hypoglycemic alarm were calculated.  The authors reported that mean glucose sensor life-span was 87 days.  The mean absolute relative difference over the range of 40-400 mg/dL for the sensors in this home-use study was 12.3% using self-monitoring of blood glucose (SMBG) as the reference.  The hypoglycemia alarm threshold was set to sound when detected glucose concentrations fell below 70 mg/dL.  The percentage of nights with hypoglycemic alarms triggered for at least 10 min was 13.6%.  Recovery of euglycemia within 30 minutes of SMBG testing was obtained in 74% of all episodes (n=20).  Hypoglycemia detection sensitivity and specificity were reported to be 77% and 96%, respectively.  The authors noted that this study demonstrated excellent performance in nocturnal hypoglycemia detection in subjects with type 1 diabetes.  They also commented that the implanted sensor appears to have an apparent lack of nocturnal sensor attenuation, or loss of sensor accuracy and sensitivity sometimes seen with standard CIGM devices, and a high specificity of the hypoglycemic alarm.  These attributes expedite the recovery from nighttime hypoglycemia.  Both of these case series are limited by their small size and lack of a comparator.

The Senseonics website provides details of the PRECISE II study, a pivotal trial involving 90 subjects.  However, the results of this trial have not been published.


At this time, continuous interstitial glucose monitoring systems (CIGMs) marketed in the United States involve the use of a patch-like sensor device that is adhered to the skin and left in place for 1 to several days before replacement.  Some of these devices are wirelessly connected and integrated with CIGMs and insulin pump devices.

The Senseonics Eversense Continuous Glucose Monitoring System involves the use of a small subcutaneously implanted interstitial glucose monitoring sensor about the size of a medication capsule.  It is wirelessly connected to a wearable receiver/transmitter which is further connected via Bluetooth to a mobile phone app.  The sensor capsule is inserted under the skin of the upper arm through a small incision in the physician's office and is intended to last for 90 days before removal and replacement.


The following codes for treatments and procedures applicable to this document are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.  

When services are Investigational and Not Medically Necessary:
For the following procedure codes for all indications, or when the code describes a procedure indicated in the Position Statement section as investigational and not medically necessary.

0446T Creation of subcutaneous pocket with insertion of implantable interstitial glucose sensor, including system activation and patient training
0447T Removal of implantable interstitial glucose sensor from subcutaneous pocket via incision
0448T Removal of implantable interstitial glucose sensor with creation of subcutaneous pocket at different anatomic site and insertion of new implantable sensor, including system activation
ICD-10 Diagnosis  
  All diagnoses

Peer Reviewed Publications:

  1. Dehennis A, Mortellaro MA, Ioacara S. Multisite study of an implanted continuous glucose sensor over 90 days in patients with diabetes mellitus. J Diabetes Sci Technol. 2015; 9(5):951-956.
  2. Kropff J, Choudhary P, Neupane S, et al. Accuracy and longevity of an implantable continuous glucose sensor in the PRECISE study: A 180-Day, Prospective, Multicenter, Pivotal Trial. Diabetes Care. 2017; 40(1):63-68.
  3. Wang X, Ioacara S, DeHennis A.  Long-term home study on nocturnal hypoglycemic alarms using a new fully implantable continuous glucose monitoring system in type 1 diabetes. Diabetes Technol Ther. 2015; 17(11):780-786.

Government Agency, Medical Society, and Other Authoritative Publications: 

  1. American Diabetes Association. Standards of Medical Care in Diabetes- 2016. Diabetes Care. 2016; 39(Suppl 2):1-112. Available at: Accessed on April 28, 2017.
Websites for Additional Information
  1. American Diabetes Association. Type 1 diabetes. Available at: Accessed on April 28, 2017.
  2. American Diabetes Association. Type 2 diabetes. Available at: Accessed on April 28, 2017.

Senseonics Eversense Continuous Glucose Monitoring System

The use of specific product names is illustrative only. It is not intended to be a recommendation of one product over another, and is not intended to represent a complete listing of all products available.

Document History
Status Date Action
Reviewed 08/03/2017 Medical Policy & Technology Assessment Committee (MPTAC) review. Updated Rationale and References sections.
New 05/04/2017 MPTAC review. Initial document development.